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Abstract  
Background: Despite its significant importance in reducing the morbidity and mortality of HIV-positive people, an-
tiretroviral therapy is associated with increased rate of metabolic syndrome. However, data on metabolic syndrome in 
HIV-infected people receiving antiretroviral therapy in Ethiopia is scarce. This study aimed to determine the preva-
lence and the associated factors of metabolic syndrome among adult HIV positive patients taking antiretroviral ther-
apy.  
Methods: A cross-sectional study was conducted from February to April, 2017 among adult 375 HIV positive patients 
taking antiretroviral therapy at Jugal Hospital, Harar, eastern Ethiopia. Demographic, clinical and anthropometric data 
were collected from each participant. Venous blood was collected and used for the measurement of glucose and lipid 
profile using Autolab 18 clinical chemistry analyzer. The International Diabetes Federation, National Cholesterol Ed-
ucation Program: Adult Treatment Panel III and Joint Interim Statement criteria were used to define metabolic syn-
drome. Data were analyzed using STATA Version 13. Bivariate and multivariable logistic regression was used to 
identify factors associated with the outcome variable. A p-value of <0.05 was considered statistically significant.  
Results: The prevalence of metabolic syndrome was 22.1 % (95% CI: 18.2, 26.6) by National Cholesterol Education 
Program: Adult Treatment Panel III criteria, 26.7% (95% CI: 22.4, 31.4) by International Diabetes Federation criteria, 
and 29.9% (95% CI: 25.4, 34.7) by Joint Interim Statement criteria. Age over 40 years (AOR=2.3; 95% CI: 1.4-3.8); 
lack of formal education (AOR=2.4; 95% CI: 112-5.4); and using tenofovir-lamivudine-lopinavir/ritonavir regimens 
(AOR=6.7; 95% CI: 1.4-32.1) were significantly associated with metabolic syndrome defined by Joint Interim State-
ment criteria.  
Conclusion: Metabolic syndrome is high among HIV-infected people receiving antiretroviral therapy. Age, educa-
tional level and regimens were significantly associated with metabolic syndrome. Therefore, regular screening for 
components of metabolic syndrome and promotion of a healthy lifestyle is recommended. 
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Introduction  
Metabolic syndrome (MS) is an interaction of various 
factors such as abdominal obesity, dyslipidemia, the 
elevation of blood pressure and insulin resistance 
which can increase the risk of developing cardiovas-
cular disease and Type 2 diabetes (Alberti et al., 2006). 
It is a global challenge which has been playing a major 
role as a marker for metabolic disorders (Eckel et al., 
2010; Rosolova and Nussbaumerova, 2011). It  in-
creases cardiovascular risk more than each single com-
ponent (Isomaa et al., 2001). The MS is  associated 
with a 2-fold increase in risk of cardiovascular dis-
eases, cardiovascular mortality, and stroke (Salvatore 
et al., 2010).  
The introduction of Antiretroviral Therapy (ART) 
modifies the course of HIV infection, improves quality 
of life and survival of patients with HIV. It has trans-
formed formerly fatal HIV/AIDS to a chronic, man-
ageable infectious disease that requires life-long treat-
ment (Narayan et al., 2014). In Ethiopia, an estimated  
0.9% men and women aged 15-49 years have been in-
fected with HIV and 71% of the eligible patients are 
currently on ART (FHAPCO, 2018).  
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HIV infection and the use of ART regimen further can 
increase the susceptibility of HIV infected patients to 
cardio-metabolic abnormalities, such as lipodystro-
phy, dyslipidemia, insulin resistance and body shape 
changes (Katoto et al., 2018; MittAl et al., 2013; Paula 
et al., 2013; Sweet, 2005; Syed and Sani, 2013). Such 
relationship increases the chance of exposure to MS 
among HIV patients (Wand et al., 2007). Furthermore, 
the long-term toxicities are emerging after prolonged 
exposure to ART, which are becoming challenges to 
the successful management of HIV infection (Narayan 
et al., 2014). 
The prevalence of MS has varied among studies and 
varies by the type of definition used. A meta-analysis 
conducted to estimate pooled prevalence of MS in the 
global HIV infected population has shown a preva-
lence of 18% based on International Diabetes Federa-
tion (IDF) criteria, 24.6% based on Adult Treatment 
Panel (ATP) and 29.6% based on Joint Interim State-
ment (JIS) (Nguyen et al., 2016). 
Several reports on the prevalence of the MS are from 
developed nations. The reported prevalence of MS 
from a review using different studies conducted on 
people living with HIV (PLWH) in high-income coun-
tries ranges from 11.2% to 45.4% (Paula et al., 2013) 
and in developing regions, the MS prevalence ranges  
from 8.4% to 47% (Naidu et al., 2017). Studies con-
ducted in several African countries report a prevalence 
of MS up to 60.6% among HIV positive patients 
(Berhane et al., 2012; Dimodi et al., 2014; Kagaruki 
et al., 2015). In Ethiopia, MS was diagnosed in 25% 
of HIV positive patients receiving ART (Tesfaye et 
al., 2014). 
The prevalence of MS is higher in PLWH than HIV 
negative. A systematic review and meta-analysis con-
ducted to estimate the pooled prevalence of MS in sub-
Saharan Africa has shown  a prevalence of 21.5% 
among people living with HIV and 12.0% among HIV 
uninfected groups (Todowede et al., 2019).  
Early detection of MS can be crucial for decision mak-
ing in health care regarding cardiovascular disease 
prevention and patient management. Despite the large 
number of studies conducted on MS in relation to HIV 
infection and ART in many parts of the world, there 
are few data on the burden of MS in HIV-infected pa-
tients in resource-limited settings, including Ethiopia. 
Hence, the current study aimed to assess the preva-
lence and associated factors of MS among HIV pa-
tients taking ART in Jugal Hospital, Harar, eastern 
Ethiopia.  
Materials and Methods 
Study area, period and design 
An institution-based cross-sectional study was con-
ducted between February and April 2017 in Jugal Hos-
pital. The hospital is found in Harar town, which is lo-
cated in east of Ethiopia, 526 km away from Addis 
Ababa, the capital city of Ethiopia. According to the 
central statistical agency census report, the total pro-
jected population of the Harari Region for 2017 is 
244,711 (CSA, 2013). During the study period, more 
than 1300 HIV positive patients were on ART at ART 
clinics of Jugal hospital.  
Study Population  
HIV positive patients who were 18 years or older and 
had been on ART for at least 6 months were the study 
population. Pregnant women, patients with hypothy-
roidism, diabetes mellitus, chronic renal failure and 
those using corticosteroids and critically ill were ex-
cluded. 
Sample size and sampling techniques 
The sample size was calculated by using a single pop-
ulation proportion formula with the following param-
eters: considering 50% prevalence of MS, 95% confi-
dence interval (Z=1.96) and a margin of error of 5%. 
Based on this, the estimated sample size was 384. The 
HIV patients taking ART and who fulfilled the inclu-
sion criteria were recruited consequently by conven-
ient sampling technique.  
Data Collection 
Face to face interview: Data were collected using a 
structured questionnaire adapted from questionnaire 
developed by WHO stepwise approach to chronic dis-
ease risk factor surveillance (WHO, 2010). The ques-
tionnaire contains socio-demographic characteristics 
(age, sex, marital status, educational status, residence 
area, occupation, ethnicity, religion) and habit of 
smoking, Khat chewing, and alcohol intake.   
Blood pressure measurements: Blood pressure (BP) 
was measured using an automated sphygmomanome-
ter by a nurse trained on ART services. Three readings 
were taken with 5 minute interval and the average of 
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the three readings was recorded as the final BP of the 
participant.  
Anthropometric measurement: The body weight 
and height were measured using a digital balance with 
height measurement attached to it. Weight was meas-
ured by placing the weighing balance on a flat hard 
surface and height was measured while a patient is fac-
ing directly ahead. Body Mass Index (BMI) was cal-
culated by dividing weight in kilogram (kg) to height 
in meter squared (m2). The BMI results were catego-
rized as obesity (BMI is ≥30 kg/m2 ), overweight (BMI 
is 25-29.99 kg/m2), normal (BMI is 18.5-24.99 kg/m2), 
and underweight (BMI is <18.5 kg/m2) (WHO, 2011). 
Waist circumference was taken at the midpoint be-
tween the lower margin of the last palpable rib and the 
top of the iliac crest while subjects were standing and 
breathing normally and with the patient wearing light 
clothe.  
Patient record review: CD4+ cell count, WHO clini-
cal stage, type and duration of ART were collected 
from the patient’s health record.  
Blood sample collection and examination: Five ml 
of fasting venous blood specimen was collected. If the 
patient had not or fasting was not observed, the blood 
sample collection was rescheduled on the next day. 
Sample collection time was recorded in the test requi-
sition form. Serum was separated by centrifuging of 
clotted blood sample. Fasting glucose level and lipid 
profile were measured using automated clinical chem-
istry analyzer (Autolab 18, Boehringer-Mannheim Di-
agnostics, USA) using reagents from the HUMAN 
Company (Human Biological Diagnostic, Germany). 
The laboratory analysis was performed by experienced 
laboratory technologist in the laboratory of Jugal hos-
pital.  
Serum glucose level was measured by the glucose ox-
idase method (GOD-PAP). Enzymatic colorimetric as-
say method was used for the measurement of total cho-
lesterol (CHOD-PAP method) and triglyceride (GPO-
PAP method). Enzymatic precipitation method was 
used for the measurement of high density lipoprotein 
cholesterol (HDL-C). Low density lipoprotein choles-
terol (LDL-C) was calculated by using Friedewald 
equation, LDL=TC-HDL-(TG/5), where TC repre-
sents total cholesterol, and TG represents triglyceride 
(Friedewald et al., 1972). 
 
Data quality control 
Data collectors were trained for three days before the 
data collection. The questionnaire was pre-tested at 
Hiwot Fana Specialized University Hospital and the 
necessary corrections were made. All the data col-
lected using the structured questionnaire were checked 
for completeness. All reagents were labeled with date 
of opening and preparation, checked for expiration 
date and storage requirements. Standard Operating 
Procedures (SOPs) and manufacturer instruction were 
adhered strictly during blood glucose and lipid profile 
measurements. Both normal and pathological quality 
control were used to verify acceptability of blood glu-
cose and lipid profile measurement. Supervision by 
the experienced laboratory staffs working in the labor-
atory was made to verify test results. 
Definition of metabolic syndrome 
According to the National Cholesterol Education Pro-
gram Adult Treatment Panel III (NCEP-ATP III) 
guidelines, MS is  defined as having three or more of 
the following criteria: waist circumference >88 cm in 
women and >102 cm in men; triglycerides ≥ 150 
mg/dl, HDL < 50 mg/dL in women and <40 mg/dL in 
men; fasting glucose ≥110 mg/dl, or blood pressure 
≥130/85 mmHg (Grundy, 2004). According to Inter-
national Diabetes Federation (IDF) criteria, MS is  de-
fined as having waist circumference (adjusted for Af-
ricans) >80 cm in women and >94 cm in men plus two 
of the following: triglycerides ≥ l50 mg/dL, HDL <40 
mg/dl in males and <50 mg/dl in females, fasting 
plasma glucose ≥100 mg/dL or hypertension (blood 
pressure ≥ 130/85 mm Hg or current receipt of medi-
cation for hypertension) (Alberti et al., 2006). Based 
on the Joint Interim Statement (JIS) criteria, MS is  de-
fined as the presence of three or more of the following 
criteria: waist circumference (adjusted for Africans) 
>80 cm in women and >94 cm in men; triglycerides ≥ 
l50 mg/dL; HDL <40 mg/dl in males and <50 mg/dl in 
females; fasting plasma glucose ≥100 mg/dL or hyper-
tension (blood pressure ≥ 130/85 mm Hg or current re-
ceipt of medication for hypertension (Alberti et al., 
2009).  
Data processing and analysis 
All the collected data were double entered into Mi-
crosoft Excel spreadsheets. Cleaning and analysis of 
the data were done using STATA software Version-13  
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STATA Corp. College Station, Texas, USA). Descrip-
tive statistics using frequency distribution were used 
to summarize the data. Binary logistic regression 
model was used to identify the independent variables 
associated with MS. All variables with P-value less 
than 0.25 in the bivariate logistic regression analysis 
were further entered into a multivariable logistic re-
gression model in order to control the effect of con-
founding variables. Crude and adjusted odds ratios 
(OR) with 95% confidence intervals (CI) were re-
ported. All statistical tests were two-sided. Kappa sta-
tistic was used to test the degree of agreement between 
the diagnostic criteria. A P-value of <0.05 was consid-
ered statistically significant.  
Ethics approval 
Ethical approval of this study was obtained from the 
Institutional Health Research Ethics Review Commit-
tee of the College of Health and Medical Sciences, Ha-
ramaya University. All the study participants were in-
formed clearly about the purpose of the investigation 
and got their informed written and signed consent to 
take part in this study. Each study participant was in-
formed of his/her physical assessment and biochemi-
cal test results. Abnormal findings were communi-
cated to their clinician for better management of the 
study subjects.  
Results  
General characteristics of the study participants  
A total of 375 study participants (97.4% response rate) 
were included in this study. Many of the respondents 
were female (70.1%). The mean age of the participants 
was 39.8 years (range 19-68 years) and some of them 
were between the ages of 31-40 years (45.3%). Of the 
375 study subjects, 60.8% were Orthodox Christians, 
93.9% were urban dwellers, and 56.0% Amhara by 
ethnicity. One hundred and fourteen (30.4%) of the 
study participants were daily laborers, and 47.2% were 
married. About one-third of the study participants 
(33.9%) had attained a primary level of education (Ta-
ble 1). 
Clinical characteristics  
Almost all of the study participants were in World 
Health Organization (WHO) stage I (96.9%), and 
47.4% were with CD4 > 500 cells/ul. The median (in-
terquartile range (IQR)) of body mass index (BMI) 
and CD4+ count of the participants were 22.9 (19.9-
26.0) and 480 (341-676), respectively. The participant 
had received ART for a median duration of 70 months 
(range 6-156 months). The most commonly prescribed 
regimen was TDF-3TC-EFV (53.9%), followed by 
AZT-3TC-NVP (23.7%), AZT-3TC-EFV (12.0%), 
and TDF-3TC-NVP (7.7%) (Table 2). 
Prevalence of Metabolic Syndrome 
According to the NCEP-ATP III criteria, the overall 
prevalence of MS was 22.1% (95% CI: 18.2, 26.6). 
Whereas, MS was 26.7% (95% CI: 22.4, 31.4) in IDF 
criteria and 29.9% (95% CI: 25.4, 34.7) in JIS criteria. 
The JIS definition gave the highest overall prevalence 
compared to IDF and NCEP-ATP III. 
A high level of agreement between the IDF and JIS 
criteria was observed (Kappa index=0.92), while there 
was a substantial level of agreement between the IDF 
and NCEP-ATP III criteria (Kappa index=0.70) and 
between JIS and NCEP-ATP III criteria (Kappa in-
dex=0.80) (Table 3). 
Prevalence of MS components 
The prevalence of MS components in this study par-
ticipants was; low HDL-Cholesterol 64.5% (95% CI: 
59.5, 69.2), high WC based on IDF and JIS criteria 
59.2% (95% CI: 54.1, 64.1) and NCEP-ATP III crite-
ria 37.3% (95% CI: 32.6, 42.3), hypertriglyceridemia 
41.9% (95% CI: 36.9, 46.9), high glucose based on 
IDF and JIS criteria 25.1% (95% CI: 20.9, 29.7) and 
NCEP-ATP III criteria 18.4% (95% CI: 14.8, 22.7), 
high blood pressure 10.9% (95% CI: 8.1, 14.5) (Table 
4). 
 From the five components used to define MS, based 
on ATP criteria, 62 (16.5%) of the study participants 
had three abnormal components, 18 (4.8%) of them 
had four abnormal components, and 3 (0.8%) of them 
had 5 abnormal components. Based on IDF criteria, 
66(17.6%) had three abnormal components, 29 (7.7%) 
had 4 abnormal components, and 4 (1.1%) had 5 ab-
normal components. Based on JIS criteria, 75 (20.0%), 
33 (8.8%) and 4 (1.1%) of the study participants had 
three, four and five abnormal components, respec-
tively. 
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Table 1: General characteristic of the study participants at Jugal Hospital, Harar, eastern Ethiopia, 2017. 
Variables  Variable Category  n=375 (%) 
Age Group 18-30 64 (17.1) 
31-40 170 (45.3) 
41-50 96 (25.6) 
>50 45 (12.0) 
Sex Male 112 (29.9) 
Female 263 (70.1) 
Residence  Urban 352 (93.9) 
Rural 23 (6.1) 
Ethnicity  
  
Amhara 210 (56.0) 
Oromo 108 (28.8) 
Gurage 20 (5.3) 
Harari 16 (4.3) 
Tigray 11 (2.3) 
Other 10 (2.7) 
Educational status 
 
No formal education 117 (31.2) 
Primary education 127 (33.9) 
Secondary education 80 (21.3) 
College/university 51 (13.6) 
Marital status  
  
Single 30 (8.0) 
Married 177 (47.2) 
Divorced/Separated 106 (28.3) 
Widowed 62 (16.5) 
Occupation  
  
Government employee 75 (20.0) 
Private work 92 (24.5) 
Labor work 114 (30.4) 
House wife 43 (11.5) 
Retired/dependent /no work 35 (9.3) 
Others* 16 (4.3) 
Religion  
  
Muslim 94 (25.1) 
Orthodox 228 (60.8) 
Protestant 47 (12.5) 
Others (Catholic and no religion) 6 (1.6) 
     *Others were farmer, prostitute and beggar 
 
Factors associated with metabolic syndrome 
In the bivariate logistic regression analysis, age, edu-
cational level, fruit consumption, WHO stage (base-
line), ART duration, and ART regimen were consid-
ered as a candidate for multivariable logistic regres-
sion analysis. In the multivariable logistic regression 
analysis, age, educational level, and ART regimen re-
mained independent predictors of MS (defined by JIS 
criteria). Those participants with age ≥40 years were 
2.3 times more likely to develop MS compared to 
those < 40 years of age (AOR=2.3; 95% CI: 1.4, 3.8). 
Those study participants who had no formal education 
were 2.4 times more likely to develop MS compared 
to those with tertiary educational level (AOR=2.4; 
95% CI: 112-5.4). Those taking TDF-3TC-LPV/r 
were 6.7 times more likely to develop MS compared 
to those taking TDF-3TC-EFV (AOR=6.7; 95% CI: 
1.4-32.1) (Table 5). 
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Table 2: Clinical characteristics of the study participants at Jugal Hospital, Harar, eastern Ethiopia, 2017. (n=375) 
Variables  Variable Category  n (%) 
BMI Median (IQR) 22.9 (19.9-26.0) 
BMI category (kg/m2) 
 
Underweight 63 (16.8) 
Normal 195 (52.0) 
Overweight 88 (23.5) 
Obese 29 (7.7) 
WHO stage Stage I 365 (97.3) 
Stage II 1 (0.27) 
Stage III 8 (2.13) 
Stage IV 1 (0.27) 
CD4 (cells/ul) Median (IQR) 480 (341-676) 
CD4 (cells/ul) 
 
>500 177 (47.2) 
200-499 170 (45.3) 
<200 28 (7.5) 
Regimen AZT-3TC-NVP 89 (23.7) 
AZT-3TC-EFV 45 (12.0) 
TDF-3TC-EFV 202 (53.9) 
TDF-3TC-NVP 29 (7.7) 
TDF-3TC-LPV/r 10 (2.7) 
ART duration (month) Median (IQR) 70 (41-97) 
ART duration 
 
< 5 years 154 (41.1) 
>= 5 years  221 (58.9) 
Abbreviations: n=number; BMI=body mass index; IQR=inter quartile range; ART=antiretroviral therapy; AZT= zidovudine; 
3TC= lamivudine; EFV=efavirenz; TDF=Tenofovir; NVP=nevirapine; LPV/r=lopinavir/ritonavir 
Table 3: Agreement between criteria used for the definition of the MS (estimated by the kappa statistics) 
Criteria  JIS IDF NCEP-ATP III 
JIS 1 0.92 0.80 
IDF  1 0.70 
NCEP-ATP III   1 
Abbreviations: NCEP-ATP III=National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III); IDF= 
International Diabetes Federation; JIS=Joint Interim Statement 
Table 4: Prevalence of MS components in HIV patients receiving ART at Jugal Hospital, Harar, eastern Ethiopia, 
2017. 
Parameters/variables   n=375 (%) 
WC (NCEP-ATP III criteria): > 102 cm in men and >88 cm in women  140  (37.3) 
WC (IDF criteria and JIS criteria): ≥ 94 cm in men and  ≥ 80 cm in women 222 (59.2) 
Glucose (NCEP-ATP III criteria): ≥110 mg/dl 69  (18.4) 
Glucose (IDF criteria and JIS criteria): ≥100 mg/dl 94 (25.1) 
Blood pressure: 130/85 mmHg 41 (10.9) 
HDL cholesterol: < 40 mg/dl in men and <50 mg/dl in women 242 (64.5) 
Triglyceride: ≥ 150 mg/dl 157 (41.9) 
Abbreviations: NCEP-ATP III=National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III); IDF= 
International Diabetes Federation; JIS=Joint Interim Statement; HDL=High density lipoprotein 
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Table 5: Bivariate and multivariable analyses for factors associated with MS among HIV patients receiving ART at 
Jugal Hospital, Harar, eastern Ethiopia, 2017. 
Variables  Variable category    
MS,         
n (%) 
Normal,     
n (%) 
COR (95% CI) AOR (95% CI) 
Age(years)  <40  42 (21.3) 155 (78.7) 1 1 
≥40 70 (39.3) 108 (60.7) 2.4 (1.5-3.8) 2.3 (1.4-3.8)* 
Education  Tertiary 12 (23.5) 39 (76.5) 1 1 
Primary  26 (20.5) 101 (79.5) 0.8 (0.4-1.8) 0.8 (0.4-1.9) 
Secondary  22 (27.5) 58 (72.5) 1.2 (0.5-2.8) 1.3 (0.6-3.1) 
No formal education 52 (44.4) 65 (55.6) 2.6 (1.2-5.5) 2.4 (1.1-5.4)* 
Fruit eat No 23 (38.3) 37 (61.7) 1 1 
 Yes  89 (28.2) 226 (71.8) 0.6 (0.4-1.1) 0.9 (0.5-1.7) 
WHO stage 
(baseline) 
Stage I 15 (22.1) 53 (77.9) 1 1 
Stage II 24 (42.1) 33 (57.9) 2.6 (1.2-5.6) 2.1 (0.9-4.8) 
Stage III 62 (29.9) 145 (70.1) 1.5 (0.7-2.9) 1.1 (0.5-2.1) 
Stage Iv 11 (25.6) 32 (74.4) 1.2 (0.5-2.9) 0.7 (0.3-1.9) 
ART duration <5 year 36 (23.4) 118 (76.6) 1 1 
≥5 year 76 (34.4) 145 (65.6) 1.7 (1.1-2.7) 1.2 (0.7-2.2) 
ART type TDF-3TC-EFV 48 (23.8) 154 (76.2) 1 1 
AZT-3TC-EFV 19 (42.2) 26 (57.8) 2.3 (1.2-4.6) 1.8 (0.8-3.9) 
AZT-3TC-NVP 30 (33.7) 59 (66.3) 1.6 (0.9-2.8) 1.7 (0.9-3.2) 
TDF-3TC-NVP 8 (27.6) 21 (72.4) 1.2 (0.5-2.9) 1.2 (0.4-3.2) 
TDF-3TC-LPV/r 7 (70.0) 3 (30.0) 7.5 (1.8-30.1) 6.7 (1.4-32.1)* 
Abbreviations: *=statistical significant, n=number; MS=metabolic syndrome; JIS=Joint Interim Statement; COR=crude odds 
ratio; AOR=adjusted odds ratio; CI=confidence interval; ART=antiretroviral therapy; AZT=zidovudine; 3TC=lamivudine; EFV= 
efavirenz; TDF=Tenofovir; NVP=nevirapine; LPV/r=lopinavir/ritonavir 
 
Discussion 
The overall prevalence of MS according to the NCEP-
ATP III and IDF criteria was 22.1% and 26.7% respec-
tively, while a relatively higher prevalence (29.9%) 
was found according to JIS definition. Age, educa-
tional level, and ART regimen remained independent 
predictors of MS.   
The prevalence of MS in the present study is  similar 
to the one found by a study from Jimma, southwest 
Ethiopia, which is 21.1% using ATP criteria (Berhane 
et al., 2012), Thailand (22.2%) (Jantarapakde et al., 
2014), and Italy (20.8%) (Bonfanti et al., 2007). But it 
is higher than the ones reported from Australia (14%) 
(Samaras et al., 2007), Barcelona, Spain (17%) (Jericó 
et al., 2005). However, our finding is slightly higher 
than the ones reported from Hawasa, southern Ethio-
pia,  which are  18.1% and 17.8 using ATP criteria; 
and 25% and 24.3% using IDF criteria (Hirigo and 
Tesfaye, 2016; Tesfaye et al., 2014), Australia (14%) 
(Samaras et al., 2007), Barcelona, Spain (17%) (Jericó 
et al., 2005). The prevalence of MS in our study is 
lower than reported in Cameroon (32.8%) (Dimodi et 
al., 2014), Taiwan (26.2%) (Wu et al., 2012), Portugal 
(41.9%) (Santos and Barros, 2007), South Africa (60.6%) 
(Erasmus et al., 2012), USA (33%) (Sobieszczyk et al., 
2008), and Ghana (61.1%) (Obirikorang et al., 2016). 
The observed variation of prevalence of MS among 
different studies could be attributed to the use of dif-
ferent definition criteria, different exposure durations 
of ART among the study participants and different 
study populations. It could also be due to the differ-
ence in the guideline used for ART and difference in 
behavioral factors among the study subjects (Jericó et 
al., 2005; Lutsey et al., 2008; Onesi and Ignatius, 
2014).   
In this study, the prevalence of MS was higher among 
those aged > 40 years. This has been reported in other 
similar studies conducted in Ethiopia, in which   the 
prevalence of MS increased noticeably in the age 
group 45 years against the age group 24 years (Tesfaye 
et al., 2014). Different studies reported that MS was 
more prevalent among old age patients than younger 
ones (Jericó et al., 2005; Magny Bergersen et al., 
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2006; Mangili et al., 2007; Wand et al., 2007). The in-
creased risk of MS in older age-group is supported by 
the fact that aging has been shown to affect the cardio-
metabolic activity (Alberti et al., 2006). 
Antiretroviral therapy has been proposed to induce MS 
in HIV-infected patients. Different types of metabolic 
abnormalities such as dyslipidemia, increased blood 
pressure, and insulin resistance were developed on 
HIV positive patients on ART (Wand et al., 2007). It 
has  also been reported that the risk of MS is  higher in  
HIV patients who use a Protease inhibitor (PIs) based 
regimen (Samaras et al., 2007). Evidence of hyper-
lipidemia dyslipidemia (both hypertriglyceridemia 
and hypercholesterolemia) were commonly observed 
during lopinavir/ritonavir (LPV/r) treatment (Muya 
and Kamuhabwa, 2019). These could be due to prote-
ase inhibitors interact with adipose tissue, altering li-
pid metabolism by generating oxidative stress which 
modifies the secretion, differentiation, and autophagic 
activities of adipocytokines that leads to metabolic ab-
normalities. 
In our study, lack of formal education was associated 
with increased odds of MS. A similar finding has  been 
reported from a study conducted in Kenya (Kiama et 
al., 2018), but it is unlike the finding of  a study done  
in Tanzania, where the prevalence of MS was signifi-
cantly greater among study participants with higher 
level of education (Kagaruki et al., 2015). 
The finding of this study has clinical and public health 
implications. Screening of MS at ART clinics is not 
frequently performed in the management of metabolic 
disorders in settings with limited resources. The find-
ing from this study implies the need for the importance 
of close monitoring of cardiovascular risk factors for 
early prevention and management of HIV patients.  
The main strengths of this study include that it pro-
vides the opportunity of evaluating the prevalence of 
MS in HIV infected patients receiving ART. This con-
tributes to improved assessment of the problem in the 
context of resource-constrained countries in which 
HIV comorbidities data are scarce and much needed. 
However, potential limitations of this study must be 
considered. Because of the convenient sampling tech-
nique was used, which cannot be considered repre-
sentative of all HIV infected patients receiving ART 
in the country. Our study design was cross-sectional 
and, as a result, it could only identify associated fac-
tors and not risk factors. 
Conclusion 
This study has indicated that MS is high among HIV-
infected patients receiving ART in our set up. Age 
above 40 years old, lack of formal education, and us-
ing TDF-3TC-LPV/r regimen were found to be inde-
pendent predictors of MS. Regular monitoring of MS 
among HIV/AIDS patients who are on ART is manda-
tory in the ART clinic. Therefore, patients with HIV 
infection on ART should be screened for components 
of MS and  provide access to affordable CVD and met-
abolic care services in order to  reduce the potential 
risk for morbidity and mortality related to long-term 
metabolic abnormalities. Regular follow up of old age 
patients and those taking TDF-3TC-LPV/r regimen is 
highly recommended. Further wide scale studies are 
recommended to evaluate the occurrence of metabolic 
syndrome using sample representative of all HIV in-
fected patients receiving ART. 
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